Omegas and dry eye: More knowledge, more questions

Optometry and Vision Science

Volumn 92, Issue 9, 2015, Pages 948-956

  Hom, Milton M ^a   Asbell, Penny ^b   Barry, Brendan ^b  

^a Private Practice   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

anti inflammatory; dry eye disease; eicosanoids; inflammation; omega 3; omega 6; polyunsaturated fatty acids

Indexed keywords

KNOWLEDGE BASED SYSTEMS; MEDICAL APPLICATIONS;

ANTI-INFLAMMATORIES; DRY EYE; EICOSANOIDS; INFLAMMATION; OMEGA-3; OMEGA-6;

POLYUNSATURATED FATTY ACIDS;

FAT INTAKE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

ADMINISTRATION AND DOSAGE; DIET SUPPLEMENTATION; DRY EYE SYNDROMES; FAT INTAKE; FEMALE; HUMAN;

DIETARY FATS; DIETARY SUPPLEMENTS; DRY EYE SYNDROMES; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; HUMANS;

EID: 84940938962     PISSN: 10405488     EISSN: 15389235     Source Type: Journal    
DOI: 10.1097/OPX.0000000000000655     Document Type: Review

References (64)

1. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Advance Data from Vital Health Statistics: Complementary and Alternative Medicine Use among Adults: United States, 2002: Publication #343. Washington, DC: Data National Center for Complementary and Alternative Medicine, National Institutes of Health; 2004:1-19. Available at: http://www.cdc.gov/nchs/data/ad/ad343.pdf. Accessed April 2, 2015.
2. Oleñ ik A. Effectiveness and tolerability of dietary supplementation with a combination of omega-3 polyunsaturated fatty acids and antioxidants in the treatment of dry eye symptoms: results of a prospective study. Clin Ophthalmol 2014;8:169-76.
3. Bhargava R, Kumar P, Kumar M, Mehra N, Mishra A. A randomized controlled trial of omega-3 fatty acids in dry eye syndrome. Int J Ophthalmol 2013;6:811-6.
4. Oleñik A, Jiménez-Alfaro I, Alejandre-Alba N, Mahillo-Fernández I. A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction. Clin Interv Aging 2013;8:1133-8.
5. Sheppard JD, Jr., Singh R, McClellan AJ, Weikert MP, Scoper SV, Joly TJ, Whitley WO, Kakkar E, Pflugfelder SC. Long-term supplementation with n-6 and n-3 PUFAs improves modera te-to-severe keratoconjunctivitis sicca: a randomized double-blind clinical trial. Cornea 2013.
6. Kangari H, Eftekhari MH, Sardari S, Hashemi H, Salamzadeh J, Ghassemi-Broumand M, Khabazkhoob M. Sho rt-term consumption of oral omega-3 and dry eye syndrome. Ophthalmology 2013;120: 2191-6.
7. Pinazo-Durán MD, Galbis-Estrada C, Pons-Vázquez S, Cantu-Dibildox J, Marco-Ramírez C, Benítez-del-Castillo J. Effects of a nutraceutical formulation based on the combination of antioxidants and omega-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders. Clin Interv Aging 2013;8:139-48.
8. Jackson MA, Burrell K, Gaddie IB, Richardson SD. Efficacy of a new prescription-only medical food supplement in alleviating signs and symptoms of dry eye, with or witho ut concomitant cyclosporine A. Clin Ophthalmol 2011;5:1201-6.
9. Brignole-Baudouin F, Baudouin C, Aragona P, Rolando M, Labetoulle M, Pisella PJ, Barabino S, Siou-Mermet R, Creuzo t-Garcher C. A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients. Acta Ophthalmol 2011;8 9:e591-7.
10. Creuzot-Garcher C, Baudouin C, Labetoulle M, Pisella PJ, Mouriaux F, Meddeb-Ouertani A, El Matri L, Khairallah M, Brignole-Baudouin F. Efficacy assessment of Nutrilarm(R), a per os om ega-3 and omega-6 polyunsaturated essential fatty acid dietary formulation versus placebo in patients with bilateral treated moderate dry eye syndrome. J Fr Ophtalmol 2011;34:448-55.
11. Wojtowicz JC, Butovi ch I, Uchiyama E, Aronowicz J, Agee S, McCulley JP. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea 2011;30:308-14.
12. Cortina MS,Bazan HE. Docosahexaenoic acid, protectins and dry eye Curr Opin Clin Nutr Metab Care 2011, 14, 132-7
13. Larmo PS, Jarvinen RL, Setala NL, Yang B, Viitanen MH, E ngblom JR, Tahvonen RL, Kallio HP. Oral sea buckthorn oil attenuates tear film osmolarity and symptoms in individuals with dry eye. J Nutr 2010;140:1462-8.
14. Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye 2008;31:141-6.
15. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc 2008;106:336-56.
16. Pinna A, Piccinini P, Carta F. Effect of oral linoleic and gammalinolenic acid on meibomian gland dysfunction. Cornea 2007;26: 260-4.
17. Creuzot C, Passemard M, Viau S, Joffre C, Pouliquen P, Elena PP, Bron A, Brignole F. Improvement of dry eye symptoms with polyunsaturated fatty acids. J Fr Ophtalmol 2006;29:868-73.
18. Aragona P, Bucolo C, Spine lla R, Giuffrida S, Ferreri G. Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjogren's syndrome patients. Invest Ophthalmol Vis Sci 2005;46: 4474-9.
19. Miljanovic B, T rivedi KA, Dana MR, Gilbard JP, Buring JE, Schaumberg DA. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr 2005;82:887-93.
20. Barabino S, Rolando M, Camicione P, Ravera G, Zanardi S, Giuffrida S, Calabria G. Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea 2003;22:97-101.
21. Wu D, Meydani M, Leka LS, Nightingale Z, Handelman GJ, Blumberg JB, Meydani SN. Effect of dietary supplementation with black currant seed oil on the immune response of healthy elderly subjects. Am J Clin Nutr 1999;70:536-43.
22. Wei Y, Asbell PA. The core mechanism of dry eye disease is inflammation. Eye Contact Lens 2014;40:248-56.
23. Simopoulos AP. Omega-6/omega-3 essential fatty acids: biological effects. World Rev Nutr Diet 2009;99:1-16.
24. Roncone M, Bartlett H, Eperjesi F. Essential fatty acids for dry eye: a review. Cont Lens Anterior Eye 2010;33:49-54.
25. Calder PC, Zurier RB. Polyunsaturated fatty acids and rheumatoid arthritis. Curr Opin Clin Nutr Metab Care 2001;4:115-21.
26. Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Jr., Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst 2013;105:1132-41.
27. Calder PC. n-3 polyunsaturated fatty acids and mononuclear phagocyte function. In: Kremer J, ed. Medicinal Fatty Acids in Inflammation. Basel, Switzerland: Birkhaüser Verlag; 1998:1-27.
28. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van derMeer JW, Cannon JG, RogersTS, KlempnerMS,Weber PC, et al. The effect of dietary supplementat ion with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-71.
29. Meydani SN, Endres S, Woods MM, Goldin BR, Soo C, Morrill-Labrode A, Dinarello CA, Gorbach SL. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr 1991;121:547-55.
30. Venkatraman JT, Chandrasekar B, Kim JD, Fernandes G. Effects of n-3 and n-6 fatty acids on the activities and expression of hepatic antioxidant enzymes in autoimmune-prone NZBxNZW F1 mice. Lipids 1994;29:561-8.
31. Purasiri P, McKechnie A, Heys SD, Eremin O. Modulation in vitro of human natural cytotoxicity, lymphocyte proliferative response to mitogens and cytokine production by essential fatty acids. Imm unology 1997;92:166-72.
32. Khan NA, Yessoufou A, Kim M, Hichami A. N-3 fatty acids modulate Th1 and Th2 dichotomy in diabetic pregnancy and macrosomia. J Autoimmun 2006;26:268-77.
33. Santoli D,Phillips PD,Colt TL,Zurier RB. Suppression of interleukin 2-dependent human T cell growth in vitro by prostaglandin E (PGE) and their precursor fatty acids. Evidence for a PGEindependent mechanism of inhibition by the fatty acids J Clin Invest 1990 85 424-32.
34. Zurier RB, Rossetti RG, Seiler CM, Laposata M. Human peripheral blood T lymphocyte proliferation after activation of the T cell receptor: effects of unsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 1999;60:371-5.
35. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002;21:495-505.
36. Oliver C, Watson H. Omega-3 fatty acids for cystic fibrosis. Cochrane Database Syst Rev 2013;11:CD002201.
37. de Oliveira Otto MC, Mozaffarian D, Kromhout D, Bertoni AG, Sibley CT, Jacobs DR, Jr., Nettleton JA. Die tary intake of saturated fat by food source and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr 2012;96:397-404.
38. Volker D, Fitzgerald P, Major G, Garg M. Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. J Rheumatol 2000;27:2343-6.
39. McCowen KC, Bistrian BR. Essential fatty acids and their derivatives. Curr Opin Gastroenterol 2005;21:207-15.
40. Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, Flabouris K, Wechalekar MD, Lee AT, Cleland LG. Fish oil in recent onse t rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis 2015;74:89-95.
41. Yates CM, Calder PC, Ed Rainger G. Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol Ther 2014;141:272-82.
42. Oliver C, Jahnke N. Omega-3 fatty acids for cystic fibrosis. Cochrane Database Syst Rev 2011:CD002201.
43. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58:2047-67.
44. Calder PC. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 2008;52:885-97.
45. Riediger ND, Othman RA, Suh M, Moghadasian MH. A systemic review of the roles of n-3 fatty acids in health and disease. J Am Diet Assoc 2009;109:668-79.
46. Goldberg RJ, Katz J. A meta-Analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 2007;129:210-23.
47. Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 2008;14:S102-6.
48. Enrí quez-de-Salamanca A, Calder V, Gao J, Galatowicz G, Garcia-Vázquez C, Fernández I, Stern ME, Diebold Y, Calonge M. Cytokine responses by conjunctival epithelial cells: an in vitro model of ocular inflammation. Cytokine 2008;44:160-7.
49. de Paiva CS, Pflugfelder SC. Rationale for anti-inflammatory therapy in dry eye syndrome. Arq Bras Oftalmol 2008;71:89-95.
50. Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol 2008;146:350-6.
51. Lee HS, Chauhan SK, Okanobo A, Nallasamy N, Dana R. Therapeutic efficacy of topical epigallocatechin gallate in murine dry eye. Cornea 2011;30:1465-72.
52. Chen Y, Chauhan SK, Saban DR, Sadrai Z, Okanobo A, Dana R. Interferon-gamma-secreting NK cells promote induction of dry eye disease. J Leukoc Biol 2011;89:965-72.
53. Epstein SP, Gadaria-Rathod N, Wei Y, Maguire MG, Asbell PA. HLA-DR expression as a biomarker of inflammation fo r multicenter clinical trials of ocular surface disease. Exp Eye Res 2013;111:95-104.
54. Wei Y, Gadaria-Rathod N, Epstein S, Asbell P. Tear cytokine profile as a noninvasive biomarker of inflam mation for ocular surface diseases: standard operating procedures. Invest Ophthalmol Vis Sci 2013;54:8327-36.
55. Massingale ML, Li X, Vallabhajosyula M, Chen D, Wei Y, Asbell PA. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009;28:1023-7.
56. Fontes JD, Rahman F, Lacey S, Larson MG, Vasan RS, Benjamin EJ, Harris WS, Robins SJ. Red blood cell fatty acids and biomarkers of inflammation: a cross-sectional study in a community-based cohort. Atherosclerosis 2015;240:431-6.
57. Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004;6:461-7.
58. Li N, He J, Schwartz CE, Gjorstrup P, Bazan HE. Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J Ocul Pharmacol Ther 2010;26:431-9.
59. Calder PC. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 2003;38:343-52.
60. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 2002;56:365-79.
61. Wilder J. Basimetric approach (law of initial value) to biological rhythms. Ann N Y Acad Sci 1962;98:1211-20.
62. Liu A, Ji J. Omega-3 essential fatty acids therapy for dry eye syndrome: a meta-Analysis of randomized controlled studies. Med Sci Monit 2014;20:1583-9.
63. Zhu W, Wu Y, Li G, Wang J, Li X. Efficacy of polyunsaturated fatty acids for dry eye syndrome: a meta-Analysis of randomized controlled trials. Nutr Rev 2014;72:662-71.
64. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:163-78.